RecruitingNot Applicable

Fabhalta Capsules Specified Drug-use Survey

Japan50 participantsStarted 2025-09-17

Plain-language summary

The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.

Who can participate

Age range0 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients who have used Fabhalta for C3 glomerulopathy (including patients with recurrent C3 glomerulopathy post renal transplant). Exclusion Criteria: * Use of iptacopan for an indication not yet approved under the Clinical Trials Act or GCP (e.g., patient-requested medical treatment, investigator-initiated clinical trial)

What they're measuring

Number of patients with infections

Timeframe: 360 Days

Trial details

NCT IDNCT07156149

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-06-30

Contact for this trial

Novartis Pharmaceuticals

+81337978748 novartis.email@novartis.com

View on ClinicalTrials.gov More C3 Glomerulopathy trials